guest ::
| Home > Publications database > Venetoclax-based salvage therapy as bridge-to-transplant is feasible and effective in patients with relapsed/refractory AML. > print |
| Home > Publications database > Venetoclax-based salvage therapy as bridge-to-transplant is feasible and effective in patients with relapsed/refractory AML. > print |
| 001 | 293338 | ||
| 005 | 20250725103649.0 | ||
| 024 | 7 | _ | |a 10.1182/bloodadvances.2024013086 |2 doi |
| 024 | 7 | _ | |a pmid:39293081 |2 pmid |
| 024 | 7 | _ | |a 2473-9529 |2 ISSN |
| 024 | 7 | _ | |a 2473-9537 |2 ISSN |
| 024 | 7 | _ | |a altmetric:173595522 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2024-01886 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Unglaub, Julia Marie |b 0 |
| 245 | _ | _ | |a Venetoclax-based salvage therapy as bridge-to-transplant is feasible and effective in patients with relapsed/refractory AML. |
| 260 | _ | _ | |a Washington, DC |c 2025 |b American Society of Hematology |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1739177634_9306 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2025 Jan 28;9(2):375-385 |
| 520 | _ | _ | |a The BCL2-inhibitor Venetoclax (VEN) in combination with hypomethylating agents (HMA) has been approved for first-line treatment of acute myeloid leukemai (AML) patients ineligible for intensive treatment. Emerging Data suggest that VEN containing treatment strategies may also be effective in relapsed/refractory (R/R) AML, however, comparative studies with conventional treatment strategies for medically fit patients as a bridge-to transplant strategy are limited. Using propensity score matching (PSM) analysis, we compared 37 R/R AML patients, who received VEN-based salvage therapy as bridge to allogeneic hematopoietic cell transplantation (allo-HCT) with 90 patients from the German Study Alliance Leukemia (SAL) AML registry, who were treated with non-VEN-containing salvage therapy according to their treating physician's choice (TPC) including intensive and non-intensive protocols. The overall response rate (ORR=CR+CRi) among all VEN patients was significantly higher compared to the TPC control cohort (62% vs. 42%; p=0.049). Overall, 73% of VEN-treated patients vs. 63% of TPC patients were successfully bridged to allo-HCT (p =0.41). After a median follow-up of 34.3 months for the VEN cohort and 21.0 months for the TPC cohort, the median overall-survival (OS) was 15.8 months (95%-CI, 10.6-NE) and 10.5 months (95%-CI, 6.8-19.6) (p=0.15), respectively. PSM revealed a trend towards improved OS for VEN patients (HR 0.70; 95%-CI, 0.41-1.22; p=0.20). Median event free survival (EFS) was significantly longer in the VEN cohort (8.0 months) compared to the TPC cohort (3.7 months) (p=0.006). In summary, our data suggests that VEN-based salvage therapy is a safe and effective bridge to allo-HCT for this difficult-to-treat AML patient population. |
| 536 | _ | _ | |a 311 - Zellbiologie und Tumorbiologie (POF4-311) |0 G:(DE-HGF)POF4-311 |c POF4-311 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 700 | 1 | _ | |a Schlenk, Richard |0 P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc |b 1 |u dkfz |
| 700 | 1 | _ | |a Middeke, Jan M |b 2 |
| 700 | 1 | _ | |a Krause, Stefan W |0 0000-0002-5259-4651 |b 3 |
| 700 | 1 | _ | |a Kraus, Sabrina |b 4 |
| 700 | 1 | _ | |a Einsele, Hermann |b 5 |
| 700 | 1 | _ | |a Kramer, Michael |b 6 |
| 700 | 1 | _ | |a Zukunft, Sven |0 0000-0002-1811-4562 |b 7 |
| 700 | 1 | _ | |a Kauer, Joseph |b 8 |
| 700 | 1 | _ | |a Renders, Simon |b 9 |
| 700 | 1 | _ | |a Katelari, Elena |b 10 |
| 700 | 1 | _ | |a Schliemann, Christoph |b 11 |
| 700 | 1 | _ | |a Pabst, Caroline |b 12 |
| 700 | 1 | _ | |a Luft, Thomas |b 13 |
| 700 | 1 | _ | |a Dreger, Peter |0 0000-0002-7429-8570 |b 14 |
| 700 | 1 | _ | |a Röllig, Christoph |0 0000-0002-3791-0548 |b 15 |
| 700 | 1 | _ | |a Bornhäuser, Martin |b 16 |
| 700 | 1 | _ | |a Müller-Tidow, Carsten |b 17 |
| 700 | 1 | _ | |a Sauer, Tim |b 18 |
| 773 | _ | _ | |a 10.1182/bloodadvances.2024013086 |g p. bloodadvances.2024013086 |0 PERI:(DE-600)2876449-3 |n 2 |p 375-385 |t Blood advances |v 9 |y 2025 |x 2473-9529 |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/293338/files/blooda_adv-2024-013086-main.pdf |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/293338/files/blooda_adv-2024-013086-main.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:293338 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-311 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Zellbiologie und Tumorbiologie |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b BLOOD ADV : 2022 |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-08-25 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-25 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b BLOOD ADV : 2022 |d 2023-08-25 |
| 920 | 1 | _ | |0 I:(DE-He78)W010-20160331 |k W010 |l Klinische Studienzentrale |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)W010-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|